Table 2 Summary of the sensitivity analysis
Parameter | Baseline hydrocele average estimate (range) | Baseline lymphedema average estimate (range) | Sources | |
|---|---|---|---|---|
Pre-control burden | ||||
Percentage of the at-risk population that develop clinical disease | 2.08% (1.04%) | 1.25% (0.63%) | [16] | |
Disability weights | ||||
Disability weights related to chronic disease | 0.128 (0.086–0.180) | 0.109 (0.073–0.154) | [17] | |
Disability weight for ADL episodes | 0.051 (0.032–0.074) | 0.051 (0.032–0.074) | [17] | |
Disease progression & incidence rates | ||||
Percentage of clinical patients who experience ADL episodes per year | 70% (45–90%) | 95% (90–95%) | ||
Frequency of ADL episodes for clinical patients (in absence of MDA) | 2 (0–7) per year | 4 (0–7) per year | ||
Average duration of an ADL episode | 4 (1–9) days | 4 (1–9) days | ||
Mean age of the benefit cohorts (years) | Cohort 1: 20 (30) Cohort 2: 20 (30) Cohort 3: 30 (40) | Cohort 1: 20 (30) Cohort 2: 20 (30) Cohort 3: 30 (40) | ||
Impact of treatment | ||||
The reduction in transmission experienced by the treated population (Benefit cohort 1) | Year 1: 50% (35%) Year 2: 75% (53%) Year 3: 88% (62%) Year 4: 94% (66%) Year 5 95% (67%) | Year 1: 50% (35%) Year 2: 75% (53%) Year 3: 88% (62%) Year 4: 94% (66%) Year 5 95% (67%) | [12] | |
Reduction in the frequency of ADL episodes by MDA (Benefit cohort 3) | 50% (15–88%) | 50% (15–88%) | ||
Percentage of chronic disease alleviated by MDA (Benefit cohort 3) | 10% (0–20%) | 15% (0–30%) | ||